

ANDREW M. CUOMO Governor **HOWARD A. ZUCKER, M.D., J.D.**Commissioner

LISA J. PINO, M.A., J.D. Executive Deputy Commissioner

Medicaid Fee- for- Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

Effective **February 4**, **2021** the following changes will be made to the Dispense Brand Name Drug when Less Expensive than the Generic Program:

Atripla and Truvada has been ADDED to the program.

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

IMPORTANT BILLING INFORMATION

Pursuant to this program prescription claims submitted to the Medicaid program **do not require** the submission of Dispense as Written/Product Selection Code of '1'; **Pharmacies should submit DAW code 9** (Substitution Allowed by Prescriber but Plan Requests Brand). Pharmacies will receive a NCPDP reject response of "22" which means missing/invalid DAW code if other DAW codes are submitted. The only exception to this, is DAW code 1 and "*Brand Medically Necessary*" on the prescription.

List of Brand Name Drugs included in this program* (updated 1/15/2021)

Advair Diskus	Diclegis	Retin-A cream
Alphagan P 0.15%	Exelon Patch	Sensipar
Androgel pump & packets	Focalin XR	Suboxone film
Apriso	Humalog U100 vial & 50-50 KwikPen	Symbicort
Atripla	Kitabis Pak	Tecfidera
Bethkis	Lialda	Tegretol suspension
Catapres-TTS	Mitigare	Tracleer tablet
Cellcept suspension	Novolog 100u/ml FlexPen & vial, Mix 70/30 FlexPen	Truvada
Ciprodex	Nuvaring	Xeloda
Concerta	ProAir HFA	Zovirax cream
Copaxone 20mg	Rapamune solution	

^{*}List is subject to change

Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs, promoting the use of the most cost-effective product.